Novo Nordisk has entered into exclusive negotiations with BIO JAG, Biocorp's main shareholder, with a view to purchasing its entire stake in Biocorp, representing 45.3% of Biocorp's share capital and 62.19% of its voting rights, at a price of 35.00 euros per share.

Certain minority shareholders, representing 19.0% of Biocorp's share capital and 13.07% of voting rights, have undertaken to transfer their shares to Novo Nordisk upon completion of Novo Nordisk's acquisition of the Control Block.

The proposed transaction would be followed by the filing by Novo Nordisk of a mandatory simplified tender offer for the remaining Biocorp shares outstanding and, if the legal conditions are met at the end of the offer, a squeeze-out procedure and the delisting of Biocorp from Euronext Growth.

Eric Dessertenne, Chief Executive Officer of Biocorp, added: "This proposed merger rewards our efforts, begun 5 years ago, to digitalize the treatment and monitoring of chronic patients, with the constant aim of making their daily lives easier. Our teams are enthusiastic about pursuing this public health mission, which will be intensified by the strength of Novo Nordisk's global presence. '

Copyright (c) 2023 CercleFinance.com. All rights reserved.